Eyecelerator @ AAO 2023

Registration and breakfast

​

• Stephen D. McLeod, MD, CEO, American Academy of Ophthalmology 

• Allen C. Ho, MD, Retina Program Director

• Gil Kliman, MD, Program Director
   

Overview and discussion of key trends and events in the 2023 ophthalmology marketplace.

​

Moderators: Gil Kliman, MD and Jim Mazzo 

Market Overview: Kristen Harmon Ingenito, Market Scope

​

Public and Private Markets: Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James

​

Panel: 

• Sebastien Allard, VP, Corporate Development Strategy, Alcon

• Jay S. Duker, MD, CEO, Eyepoint Pharmaceuticals

• Adrienne L. Graves, PhD, Former Board Chair, IvericBio

• Wende Hutton, MBA, General Partner, Canaan Partners

​

Significant financial commitments are required for FDA clearance of new products. As global strategics increasingly delay investment, how can pioneering companies persevere?

​

Moderators: Zaina Al-Mohtaseb, MD and Nicole R. Fram, MD

Panel: 

• Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James

• Kendra Hileman, Head of Instrumentation R&D, Alcon

• Sean Ianchulev, Eyenovia 

• Philip Kowalczyk, VP, Business Development, Johnson & Johnson Vision

• Mariam Maghribi, Chief Business Officer, Shifamed

• Ramin Valian, VP, US Eyecare, Allergan, an AbbVie Company
   

Networking Break –  Marriott Grand Ballroom Foyer
 

With the approval of two new drugs and multiple other pathways under investigation in human trials, new treatments for GA have the potential to revolutionize patient care. 

​

Moderators: Robert L. Avery, MD and Aleksandra V. Rachitskaya, MD 

​

Presentations: 

• ONL Therapeutics: David Esposito, CEO

• Annexon Biosciences: Douglas Love, Esq., President & CEO

• Lineage Cell Therapeutics: Brian Culley, CEO 

• Aviceda Therapeutics: Mohamed A. Genead, MD, Co-Founder, CEO & President

• Apellis: Cedric Francois, MD, CEO

• Iveric Bio: Erin Henry, VP, Strategy & Innovation

Panel: 

• Wiley Chambers, MD, Director, Division of Ophthalmology, FDA  

• Cedric Francois, MD, CEO, Apellis

• Erin Henry, VP, Strategy & Innovation, Iveric Bio

• Daniel Lyons, PhD, CFA, Janus Henderson Investors

• Namrata Saroj, OD, Principal, All Eyes Consulting 

​

Back by popular demand! The Shark Tank-style competition features pitches from three early-stage ophthalmology innovators, with judges and the audience deciding who will take home cash prizes worth $45,000.

​

Moderators: Vance Thompson, MD and Robert Warner ​

Finalists: 

• Niki Bayat, PhD – AesculaTech Humidifeye 
  Mentor: Leonard Borrmann, PharmD

• Oussama Boundaoui, MD – Regenoptics Tamponading Hydrogel  
  Mentor: Shravanthi Reddy, PhD 

• David Kleinman, MD – Calm Water Therapeutics, LLC
  Mentor: Robert Dempsey 
   

Judges: ​

• Adrienne L. Graves, PhD, Former Board Chair, Iveric Bio 

• ​Richard L. Lindstrom, Founder, Minnesota Eye Associates

• Angela Macfarlane, CEO, Perceive

• Jim Mazzo, Executive Chairman, Neurotech Pharmaceuticals  

​​

Enjoy a bite to eat with your colleagues.
 

Forty companies present innovative new treatments, products and services. Breakout rooms will operate simultaneously for each segment. Follow these links for showcase schedules:

​

Retina Showcase: Nob Hill Room
 

Anterior Segment Showcase: Salons 11 – 14
 

Glaucoma + Digital Showcase: Salons 3 – 5

Networking Break 

​

Listen and learn from strategics, start-ups and biotech investors on what it takes to successfully get ophthalmic innovations to market and efficiently improve quality of life for patients.

​

Moderators: Allen C. Ho, MD and Robert L. Avery, MD 

Panel:

​​

• Anthony P. Adamis, MD, Chief Scientific Officer, EyeBio
  David Bingaman, Chief Development Officer, Ora
• Christoper Brittain, MBBS, Head of Global Development, Genentech
• Wiley Chambers, MD, Director, Division of Ophthalmology, FDA
• Lori-Ann Christie, PhD, Principal, Visionary Ventures
• Steve Pakola, MD, Chief Medical Officer, REGENXBIO
• Richard Small, CEO, Neurotech 
• Robert Vitti, MD, Vice President, Regeneron
   

Uncover the secrets of why some AI concepts spur vigorous investment while others struggle to gain traction. 

​

Moderators: Julie M. Schallhorn, MD, MS and Lejla Vajzovic, MD 
 

Keynote Speaker: 

The AI Gold Rush?  A Matter of Perception 

Khizer R. Khaderi, MD, MPH, Director, Stanford Human Perception Lab

​

Presentations: 

​

• AI – Generative: Vivek Natarajan, AI Researcher, Google  
   

• AI – Screening: Kester Nahen, PhD, CEO Notal Vision 
   

• AI – Image Analysis: Kaushal Solanki, Eyenuk   
   

• AI – Big Pharma: Victor Chong, MD, Global Head of Retina, Janssen

Panel: ​

• Victor Chong, MD, VP, Global Head of Retina, Janssen

• Malvenia Eydelman, MD, Director, FDA

• Ranya Habash, MD, CEO, LifeLong Viion

• Vivek Natarajan, AI Researcher, Google

• Kester Nahen, PhD, CEO, Notal Vision 

​

Examine the relevance of current Patient Reported Outcomes (PROs) and the feasibility of new draft guidance for retina treatments. 

​

Moderator:  Arsham Sheybani, MD and Charles Wykoff, MD, PhD

Panel: 

• David S. Boyer, MD, Sr Partner, Retina Vitreous Associates 

• Wiley Chambers, MD, Director, Division of Ophthalmology, FDA

• Malvina Eydelman, MD, Director, CDFH/FDA

• Gus Gazzard, MD, Director, Moorfields Eye Hospital

• Chuck Hess, Global VP Commercial Development and Digital Health, Bausch + Lomb

• Eris Jordan, OD, VP Global Clinical and Medical Affairs, Aurion Biotech

• Gary D. Novack, PhD, President, PharmaLogic Development 

• Steven C. Schallhorn, MD, Chief Medical Officer, Zeiss           

​​

The program committee wraps the day with insights and People's Choice recognition.

    ​

• Zaina Al-Mohtaseb, MD, Program Co-Chair

• Robert L. Avery, MD, Program Co-Chair 

• Gil Kliman, MD, Program Director
   

Enjoy refreshments and connect!

​